Trials / Completed
CompletedNCT01977170
Safety of Hib Vaccine (Bio Farma)
Phase 1 Study of Hib Vaccine (Bio Farma)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- PT Bio Farma · Industry
- Sex
- All
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Accepted
Summary
The objective of this study was to know the safety of Hib/PRP-T vaccine and immediate reactions within the first 30 minutes after injection.
Detailed description
This trial was an open-label study, no randomization, and no placebo or control group. Total 25 young healthy adult (volunteers) followed this trial. The safety was assessed within 24 hours, 48 hours, 72 hours, and 28 days after injection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Hib/PRP-T vaccine | Hib liquid vaccine |
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2010-12-01
- Completion
- 2010-12-01
- First posted
- 2013-11-06
- Last updated
- 2013-11-06
Locations
1 site across 1 country: Indonesia
Source: ClinicalTrials.gov record NCT01977170. Inclusion in this directory is not an endorsement.